Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Initial Efficacy of AHB-137 in Healthy Volunteers and Chronic Hepatitis B Patients
NCT05717686Phase 1Completed
- Sponsor
- AusperBio
- Start
- Feb 2023
- Primary completion
- Jan 2025
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial of AHB-137 in Chronic Hepatitis B (CHB) (7 arms), sponsored by AusperBio. Primary endpoint: Treatment-Emergent Adverse Events up to 204 days. Started Feb 2023; status: completed.
02
Drugs
AHB-137
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05717686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05717686.